Latest
By Patrick Kulp / Friday, November 15th, 2013 / Central Coast, Real Estate, Top Stories, Tri-County Economy / Comments Off on Study: Skilled workers priced out of San Luis Obispo
The findings highlight a pervasive mismatch between the high price of even starter homes and the number of jobs that pay wages high enough to support those prices. Experts say the gap is a significant roadblock to the state’s economic growth.
Read More →
Latest
By Tom Bronzini / Friday, November 15th, 2013 / Central Coast, Columns, Tourism, Wine & Viticulture / Comments Off on Shale Oak Winery turns heads with design and green focus
Shale Oak Winery’s tasting room in Paso Robles is one of the more eye-catching in the area with its colorful, angular facade of stained glass in a geometric pattern.
Read More →
Latest
By Stephen Nellis / Friday, November 15th, 2013 / Technology, Tri-County Economy / Comments Off on No cap on winners: Former P&G exec outlines AB32 strategies
“It became evident that, if you don’t think creatively about AB32, it could really restrict your business’ growth,” Hullar said. “But if you play your strategies right, you can make a lot of money with AB32 – if somebody is buying, that means somebody is selling.”
Read More →
Latest
By Stephen Nellis / Friday, November 15th, 2013 / East Ventura County, Features, Technology, Top Stories, Tri-County Economy / Comments Off on ValueClick reboots: Online advertising firm to sell assets, rename
The $1.6 billion Westlake Village-based digital advertising company has been under fire from investors — and trial attorneys — for its reliance acquisitions to produce revenue growth. It has also faced criticism of the steep losses it has taken on selling off business lines that didn’t work out.
Read More →
Latest
By Staff Report / Thursday, November 7th, 2013 / East Ventura County, Technology, Top Stories / Comments Off on ImmunGene raises $9M
Thousand Oaks-based ImmunGene, a cancer treatment firm led by a former Amgen scientist, has raised $9 million from Ally Bridge Group, an investment group with ties to Hong Kong.
ImmunGene’s so-called antibody-cytokine fusion technology could help improve the cancer-cell targeting in therapies. President and CEO Sanjay D. Khare was formerly the scientific director at Amgen, the biotech giant. Prior to the funding, ImmunGene had received several hundred thousand dollars in federal research grants.
Read More →